Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, has announced it will release its second quarter 2024 financial results on August 1, 2024. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update.
Investors can access the webcast through the Events & Presentations page on Syndax's website or join the conference call using the provided dial-in numbers. For those unable to attend, a replay will be available on the company's website for 90 days following the call.
Syndax Pharmaceuticals (Nasdaq: SNDX), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di terapie innovative per il cancro, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 il 1 agosto 2024. L'azienda organizzerà una conference call e un webcast audio dal vivo alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento sull'attività.
Gli investitori possono accedere al webcast attraverso la pagina Eventi & Presentazioni del sito web di Syndax o partecipare alla conference call utilizzando i numeri di accesso forniti. Per coloro che non possono partecipare, sarà disponibile una registrazione sul sito dell'azienda per 90 giorni dopo la chiamata.
Syndax Pharmaceuticals (Nasdaq: SNDX), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias innovadoras para el cáncer, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 1 de agosto de 2024. La empresa llevará a cabo una conferencia telefónica y una transmisión de audio en vivo a las 4:30 p.m. ET el mismo día para discutir los resultados y proporcionar una actualización del negocio.
Los inversores pueden acceder a la transmisión a través de la página de Eventos y Presentaciones en el sitio web de Syndax o unirse a la conferencia telefónica utilizando los números de acceso proporcionados. Para aquellos que no puedan asistir, habrá una repetición disponible en el sitio web de la empresa durante 90 días después de la llamada.
신닥스 제약(Syndax Pharmaceuticals, Nasdaq: SNDX)은 혁신적인 암 치료제를 개발하는 데 집중하는 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 1일에 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 결과를 논의하고 사업 업데이트를 제공하기 위해 컨퍼런스 콜 및 생방송 오디오 웹캐스트를 개최합니다.
투자자들은 신닥스 웹사이트의 이벤트 및 프레젠테이션 페이지를 통해 웹캐스트에 접근하거나 제공된 전화 접속 번호를 사용하여 컨퍼런스 콜에 참여할 수 있습니다. 참석할 수 없는 분들을 위해, 회의 이후 90일 동안 회사 웹사이트에서 재생할 수 있는 기록이 제공됩니다.
Syndax Pharmaceuticals (Nasdaq: SNDX), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies innovantes contre le cancer, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 1er août 2024. L'entreprise tiendra une conférence téléphonique et un webcast audio en direct à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour commerciale.
Les investisseurs peuvent accéder au webcast via la page Événements & Présentations du site Web de Syndax ou rejoindre la conférence téléphonique en utilisant les numéros d'accès fournis. Pour ceux qui ne peuvent pas assister, une rediffusion sera disponible sur le site de l'entreprise pendant 90 jours après l'appel.
Syndax Pharmaceuticals (Nasdaq: SNDX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Krebsbehandlungen konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 1. August 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast abhalten, um die Ergebnisse zu diskutieren und ein Update zum Geschäft zu geben.
Investoren können über die Seite Veranstaltungen & Präsentationen auf der Website von Syndax auf den Webcast zugreifen oder die bereitgestellten Einwahlnummern verwenden, um an der Telefonkonferenz teilzunehmen. Für diejenigen, die nicht teilnehmen können, wird eine Aufzeichnung 90 Tage nach der Konferenz auf der Website des Unternehmens verfügbar sein.
- None.
- None.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, August 1, 2024 to discuss the Company's financial results and provide a business update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax2Q24
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX2Q24.cfm
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-second-quarter-2024-financial-results-and-host-conference-call-and-webcast-on-august-1-2024-302206073.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
When will Syndax Pharmaceuticals (SNDX) release its Q2 2024 financial results?
What time is Syndax's (SNDX) Q2 2024 earnings call scheduled for?
How can investors access Syndax's (SNDX) Q2 2024 earnings call?
Will there be a replay available for Syndax's (SNDX) Q2 2024 earnings call?
